Altimmune, Inc.

NASDAQ:ALT

5.59 (USD) • At close May 9, 2025
Bedrijfsnaam Altimmune, Inc.
Symbool ALT
Munteenheid USD
Prijs 5.59
Beurswaarde 430,506,583
Dividendpercentage 0%
52-weken bereik 3.553 - 11.16
Industrie Biotechnology
Sector Healthcare
CEO Dr. Vipin K. Garg Ph.D.
Website https://altimmune.com

An error occurred while fetching data.

Over Altimmune, Inc.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is

Vergelijkbare Aandelen

Kamada Ltd. logo

Kamada Ltd.

KMDA

4.23 USD

XOMA Corporation logo

XOMA Corporation

XOMA

24.19 USD

Nuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc.

NVCT

8.99 USD

G1 Therapeutics, Inc. logo

G1 Therapeutics, Inc.

GTHX

7.16 USD

Alpha Teknova, Inc. logo

Alpha Teknova, Inc.

TKNO

6.96 USD

Semler Scientific, Inc. logo

Semler Scientific, Inc.

SMLR

34.79 USD

Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc.

TRDA

8.38 USD

Accuray Incorporated logo

Accuray Incorporated

ARAY

1.51 USD

Sutro Biopharma, Inc. logo

Sutro Biopharma, Inc.

STRO

0.872 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)